Serum levels of brain-derived neurotrophic factor correlate with the number of T2 MRI lesions in multiple sclerosis

Brazilian Journal of Medical and Biological Research

Volumn 45, Issue 1, 2012, Pages 68-71

  Comini Frota, E R ^a   Rodrigues, D H ^a   Miranda, E C ^b   Brum, D G ^c   Kaimen Maciel, D R ^d   Donadi, E A ^c   Teixeira, A L ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Ecoar Diagnostic Center   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d STATE UNIVERSITY OF LONDRINA   (Brazil)

Author keywords

BDNF; Biomarkers; Multiple sclerosis; Neuroimaging; Neurotrophins

Indexed keywords

BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; GADOLINIUM;

ADULT; AGED; ARTICLE; BRAIN DAMAGE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN BLOOD LEVEL; RADIODIAGNOSIS; RADIOLOGIST;

EID: 84855902750     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2011007500165     Document Type: Article

References (26)

1. Polman CH, Wolinsky JS, Reingold SC. Multiple sclerosis diagnostic criteria: three years later. Mult Scler 2005; 11: 5-12.
2. Rashid W, Miller DH. Recent advances in neuroimaging of multiple sclerosis. Semin Neurol 2008; 28: 46-55.
3. Amato MP, Portaccio E, Goretti B, Zipoli V, Battaglini M, Bartolozzi ML, et al. Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis. Arch Neurol 2007; 64: 1157-1161.
4. Rudick RA, Lee JC, Simon J, Fisher E. Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study. Ann Neurol 2006; 60: 236-242.
5. Audoin B, Guye M, Reuter F, Au Duong MV, Confort-Gouny S, Malikova I, et al. Structure of WM bundles constituting the working memory system in early multiple sclerosis: a quantitative DTI tractography study. Neuroimage 2007; 36: 1324-1330.
6. Teunissen CE, Dijkstra C, Polman C. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol 2005; 4: 32-41.
7. Ottervald J, Franzen B, Nilsson K, Andersson LI, Khademi M, Eriksson B, et al. Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers. J Proteomics 2010; 73: 1117-1132.
8. Reichardt LF. Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci 2006; 361: 1545-1564.
9. Laske C, Stransky E, Leyhe T, Eschweiler GW, Maetzler W, Wittorf A, et al. BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls. J Psychiatr Res 2007; 41: 387-394.
10. Scalzo P, Kummer A, Bretas TL, Cardoso F, Teixeira AL. Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson's disease. J Neurol 2010; 257: 540-545.
11. De Santi L, Cantalupo L, Tassi M, Raspadori D, Cioni C, Annunziata P. Higher expression of BDNF receptor gp145trkB is associated with lower apoptosis intensity in T cell lines in multiple sclerosis. J Neurol Sci 2009; 277: 65-70.
12. Azoulay D, Urshansky N, Karni A. Low and dysregulated BDNF secretion from immune cells of MS patients is related to reduced neuroprotection. J Neuroimmunol 2008; 195: 186-193.
13. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
14. Linker RA, Lee DH, Demir S, Wiese S, Kruse N, Siglienti I, et al. Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis. Brain 2010; 133: 2248-2263.
15. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
16. Filippi M, Paty DW, Kappos L, Barkhof F, Compston DA, Thompson AJ, et al. Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study. Neurology 1995; 45: 255-260.
17. Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol 2002; 15: 239-245.
18. Teixeira AL, Barbosa IG, Diniz BS, Kummer A. Circulating levels of brain-derived neurotrophic factor: correlation with mood, cognition and motor function. Biomark Med 2010; 4: 871-887.
19. Zivadinov R, Stosic M, Cox JL, Ramasamy DP, Dwyer MG. The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome. J Neurol 2008; 255 (Suppl 1): 61-74.
20. Simon JH. MRI in multiple sclerosis. Phys Med Rehabil Clin N Am 2005; 16: 383-409, viii.
21. Nagahara AH, Merrill DA, Coppola G, Tsukada S, Schroeder BE, Shaked GM, et al. Neuroprotective effects of brainderived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med 2009; 15: 331-337.
22. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001; 293: 493-498.
23. Sarchielli P, Greco L, Stipa A, Floridi A, Gallai V. Brain-derived neurotrophic factor in patients with multiple sclerosis. J Neuroimmunol 2002; 132: 180-188.
24. Frota ER, Rodrigues DH, Donadi EA, Brum DG, Maciel DR, Teixeira AL. Increased plasma levels of brain derived neurotrophic factor (BDNF) after multiple sclerosis relapse. Neurosci Lett 2009; 460: 130-132.
25. Patanella AK, Zinno M, Quaranta D, Nociti V, Frisullo G, Gainotti G, et al. Correlations between peripheral blood mononuclear cell production of BDNF, TNF-alpha, IL-6, IL-10 and cognitive performances in multiple sclerosis patients. J Neurosci Res 2010; 88: 1106-1112.
26. Weinstock-Guttman B, Zivadinov R, Tamano-Blanco M, Abdelrahman N, Badgett D, Durfee J, et al. Immune cell BDNF secretion is associated with white matter volume in multiple sclerosis. J Neuroimmunol 2007; 188: 167-174.